IceCure Medical Reports Record 2025 ProSense Sales and Increased U.S. Demand
I'm PortAI, I can summarize articles.
IceCure Medical Ltd. reported record sales of its ProSense® cryoablation system, totaling approximately $3.4 million for the year ended December 31, 2025. The growth is attributed to increased U.S. demand following FDA marketing authorization for treating low-risk breast cancer, along with record sales in Europe. As of December 31, 2025, the company had approximately $8.9 million in cash and cash equivalents. Additionally, there was a record number of peer-reviewed publications and presentations on ProSense®'s applications in various cancers. These results are preliminary and unaudited.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments